Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 1)]

Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 1)] Publisher

Avagimyan AA^{11, 12} ; Sheibani M^{13, 14} ; Trofimenko AI¹⁵ ; Lysov EE¹⁵ ; Khamidova FM¹⁶ ; Aznauryan AZ¹⁷ ; Sukiasyan LM¹⁸ ; Sahakyan KT¹⁷ ; Gevorgyan TR¹⁹ ; Tatoyan MR¹⁷ ; Mkrtchyan GL¹⁷ ; Meltonyan GL¹⁷ ; Petrosyan AR²⁰ ; Martemyanova LA²¹ Show All Authors

Avagimyan AA^{11, 12}
Sheibani M^{13, 14}
Trofimenko AI¹⁵
Lysov EE¹⁵
Khamidova FM¹⁶
Aznauryan AZ¹⁷
Sukiasyan LM¹⁸
Sahakyan KT¹⁷
Gevorgyan TR¹⁹
Tatoyan MR¹⁷
Mkrtchyan GL¹⁷
Meltonyan GL¹⁷
Petrosyan AR²⁰
Martemyanova LA²¹
Petrosyan RR²²
Urazova OI^{23, 24}
Pogosova NV^{10, 12}
Sarrafzadegan N²⁵

Show Affiliations

1. Isfahan University of Medical Sciences, Isfahan, Iran
2. Patrice Lumumba Peoples’ Friendship University of Russia, Moscow, Russian Federation
3. Iran University of Medical Sciences, Tehran, Iran
4. Kuban State Medical University, Krasnodar, Russian Federation
5. Samarkand State Medical University, Samarkand, Uzbekistan
6. Yerevan State Medical University after M. Heratsi, Yerevan, Armenia
7. Gomel State Medical University, Gomel, Belarus
8. Lebanese American University, Beirut, Lebanon
9. Siberian State Medical University, Tomsk, Russian Federation
10. National Medical Research Centre of Cardiology named after Academician E.I. Chazov, Moscow, Russian Federation
11. Institute of Cardiovascular Research, Isfahan University of Medical Sciences, Isfahan, Iran
12. Department of Evidence-Based Medicine, Institute of Medicine, Patrice Lumumba Peoples’ Friendship University of Russia, Moscow, Russian Federation
13. The Department of Pharmacology
14. Razi Drug Research Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
15. The Pathological Physiology Department, Kuban State Medical University, Krasnodar, Russian Federation
16. The Pathological Anatomy Department, Samarkand State Medical University, Samarkand, Uzbekistan
17. The Histology Department, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia
18. Central Research Laboratory, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia
19. The Pediatric Ophthalmology Department, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia
20. The Department of Pathological Anatomy and Clinical Morphology, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia
21. The Pathological Anatomy Department, Gomel State Medical University, Gomel, Belarus
22. Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Beirut, Lebanon
23. The Russian Academy of Sciences, Russian Federation
24. The Patho-physiology Department, Siberian State Medical University, Tomsk, Russian Federation
25. The Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Innovative Medicine of Kuban Published:2024

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a revolutionary class of drugs with far-reaching protective effects in multiple organs. The protective potential of SGLT2i is much broader than that of the classical concept of glucose control and consists of an entire conglomerate of associated pleiotropic effects. This study aims to provide a descriptive review of the pleiotropic therapeutic potential of SGLT2i. The first part of the literature review examined the use of SGLT2i in cardiology and nephrology. The use of SGLT2i represents an innovative approach to improving patients’ quality of life and course of heart failure and chronic kidney disease, regardless of left ventricular ejection fraction and type 2 diabetes. © 2024 Scientific Research Institute — Ochapovsky Clinical Regional Hospital no. 1. All rights reserved.

Related Docs

View other Related Docs

1. Sodium-Glucose Co-Transporter 2 Inhibitors (Sglt2i); As a Preventive Factor of Kidney Failure in Patients With Type 2 Diabetes; a Meta-Analysis of Randomized Controlled Trials, Journal of Renal Injury Prevention (2021)

2. Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 2)], Innovative Medicine of Kuban (2025)

3. Administration of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Patients With Diabetes: A Systematic Review and Meta-Analysis, Journal of Nephropathology (2023)

4. Antianginal Effects of Empagliflozin in Patients With Type 2 Diabetes And Refractory Angina; a Randomized, Double-Blind Placebo-Controlled Trial (Empt-Angina Trial), Clinical Cardiology (2024)

5. Dapagliflozin in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis on Randomized, Double-Blind, Placebo-Controlled Multicenter Trials, Journal of Nephropathology (2025)

6. Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Insulin Resistance; a Systematic Review and Meta-Analysis, Acta Diabetologica (2023)

7. Association Between Sglt2 (Sodium-Glucose Cotransporter-2) Inhibitors and Bladder Cancer in Individuals With Type 2 Diabetes; a Systematic Review and Meta-Analysis, Journal of Nephropathology (2023)

8. Investigating the Association Between the Administration of Sglt-2 Inhibitors and the Risk of Urinary Tract Infection; a Systematic Review and Meta-Analysis, Journal of Renal Injury Prevention (2024)

Experts (# of related papers)

View all Related Experts

Nizal Sarrafzadegan (3)

Shiva Seirafian (2)

Style	Citing Format
MLA	Avagimyan AA, et al.. "Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 1)]." Innovative Medicine of Kuban, vol. 9, no. 4, 2024, pp. 126-135.
APA	Avagimyan AA, Sheibani M, Trofimenko AI, Lysov EE, Khamidova FM, Aznauryan AZ, Sukiasyan LM, Sahakyan KT, Gevorgyan TR, Tatoyan MR, Mkrtchyan GL, Meltonyan GL, Petrosyan AR, Martemyanova LA, Petrosyan RR, Urazova OI, Pogosova NV, Sarrafzadegan N (2024). Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 1)]. Innovative Medicine of Kuban, 9(4), 126-135.
Chicago	Avagimyan AA, Sheibani M, Trofimenko AI, Lysov EE, Khamidova FM, Aznauryan AZ, Sukiasyan LM, et al.. "Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 1)]." Innovative Medicine of Kuban 9, no. 4 (2024): 126-135.
Harvard	Avagimyan AA et al. (2024) 'Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 1)]', Innovative Medicine of Kuban, 9(4), pp. 126-135.
Vancouver	Avagimyan AA, Sheibani M, Trofimenko AI, Lysov EE, Khamidova FM, Aznauryan AZ, et al.. Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 1)]. Innovative Medicine of Kuban. 2024;9(4):126-135.
BibTex	@article{ author = {Avagimyan AA and Sheibani M and Trofimenko AI and Lysov EE and Khamidova FM and Aznauryan AZ and Sukiasyan LM and Sahakyan KT and Gevorgyan TR and Tatoyan MR and Mkrtchyan GL and Meltonyan GL and Petrosyan AR and Martemyanova LA and Petrosyan RR and Urazova OI and Pogosova NV and Sarrafzadegan N}, title = {Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 1)]}, journal = {Innovative Medicine of Kuban}, volume = {9}, number = {4}, pages = {126-135}, year = {2024} }
RIS	TY - JOUR AU - Avagimyan AA AU - Sheibani M AU - Trofimenko AI AU - Lysov EE AU - Khamidova FM AU - Aznauryan AZ AU - Sukiasyan LM AU - Sahakyan KT AU - Gevorgyan TR AU - Tatoyan MR AU - Mkrtchyan GL AU - Meltonyan GL AU - Petrosyan AR AU - Martemyanova LA AU - Petrosyan RR AU - Urazova OI AU - Pogosova NV AU - Sarrafzadegan N TI - Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 1)] JO - Innovative Medicine of Kuban VL - 9 IS - 4 SP - 126 EP - 135 PY - 2024 ER -

Style

Citing Format

MLA

Avagimyan AA, et al.. "Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 1)]." Innovative Medicine of Kuban, vol. 9, no. 4, 2024, pp. 126-135.

APA

Avagimyan AA, Sheibani M, Trofimenko AI, Lysov EE, Khamidova FM, Aznauryan AZ, Sukiasyan LM, Sahakyan KT, Gevorgyan TR, Tatoyan MR, Mkrtchyan GL, Meltonyan GL, Petrosyan AR, Martemyanova LA, Petrosyan RR, Urazova OI, Pogosova NV, Sarrafzadegan N (2024). Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 1)]. Innovative Medicine of Kuban, 9(4), 126-135.

Chicago

Avagimyan AA, Sheibani M, Trofimenko AI, Lysov EE, Khamidova FM, Aznauryan AZ, Sukiasyan LM, et al.. "Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 1)]." Innovative Medicine of Kuban 9, no. 4 (2024): 126-135.

Harvard

Avagimyan AA et al. (2024) 'Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 1)]', Innovative Medicine of Kuban, 9(4), pp. 126-135.

Vancouver

Avagimyan AA, Sheibani M, Trofimenko AI, Lysov EE, Khamidova FM, Aznauryan AZ, et al.. Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 1)]. Innovative Medicine of Kuban. 2024;9(4):126-135.

BibTex

@article{ author = {Avagimyan AA and Sheibani M and Trofimenko AI and Lysov EE and Khamidova FM and Aznauryan AZ and Sukiasyan LM and Sahakyan KT and Gevorgyan TR and Tatoyan MR and Mkrtchyan GL and Meltonyan GL and Petrosyan AR and Martemyanova LA and Petrosyan RR and Urazova OI and Pogosova NV and Sarrafzadegan N}, title = {Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 1)]}, journal = {Innovative Medicine of Kuban}, volume = {9}, number = {4}, pages = {126-135}, year = {2024} }

RIS

TY - JOUR
AU - Avagimyan AA
AU - Sheibani M
AU - Trofimenko AI
AU - Lysov EE
AU - Khamidova FM
AU - Aznauryan AZ
AU - Sukiasyan LM
AU - Sahakyan KT
AU - Gevorgyan TR
AU - Tatoyan MR
AU - Mkrtchyan GL
AU - Meltonyan GL
AU - Petrosyan AR
AU - Martemyanova LA
AU - Petrosyan RR
AU - Urazova OI
AU - Pogosova NV
AU - Sarrafzadegan N
TI - Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 1)]
JO - Innovative Medicine of Kuban
VL - 9
IS - 4
SP - 126
EP - 135
PY - 2024
ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract